Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 322 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Vancomycin hydrochloride Clear all

Conditions: Overweight and Obesity
Interventions: Synbiotic Group, Placebo Group; Dietary Supplement · Other
Lead sponsor: Texas Christian University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Infections, Pediatrics
Interventions: Ceftaroline fosamil, Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam, Cephalexin or Clindamycin or Linezolid; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 28
States / cities: Phoenix, Arizona • Orange, California • San Diego, California + 23 more

Conditions: Sepsis, Critical Illness, Infections, Drug Toxicity
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 17 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Hepatocellular Carcinoma, Hepatocellular Carcinoma
Interventions: vancomycin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sepsis, Sepsis Mrsa, Sepsis Bacteremia, Antimicrobial - Induced Nephropathy, Sepsis, Severe, Septic Shock, Septic Syndrome
Interventions: Multifaceted de-implementation strategy to reduce vancomycin overuse; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 52,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Bacteremia
Interventions: Vancomycin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more

Conditions: Total Knee Arthroplasty
Interventions: Intraosseous Vamcomycin Administration; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Diego, California

Conditions: Burns
Interventions: Sulfamylon® For 5 % Topical Solution, Topical Antimicrobial/Antifungal Medications; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 3 Months and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 9
States / cities: Mobile, Alabama • Redlands, California • Gainesville, Florida + 6 more

Conditions: Biomarkers, Acute Kidney Injury, Sepsis
Interventions: Not listed
Lead sponsor: Nutromics; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Oakland, California • San Francisco, California • Stanford, California + 2 more

Conditions: Chronic Heart Failure
Interventions: MTP-101-C encapsulated Microbiota, Vancomycin, Neomycin; Biological · Drug
Lead sponsor: Melana Yuzefpolskaya, MD; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Bacteremia
Interventions: dalbavancin; Drug
Lead sponsor: Vicuron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: Osteomyelitis, Methicillin-resistant Staphylococcus Aureus
Interventions: trimethoprim-sulfamethoxazole, vancomycin; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Rhinosinusitis (Diagnosis)
Interventions: Saline Nasal, Budesonide Nasal, Topical Antibacterial (Product); Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Clostridium Difficile Infection
Interventions: Vancomycin, Fidaxomicin; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions: delafloxacin, vancomycin, aztreonam; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 31
States / cities: Mobile, Alabama • Montgomery, Alabama • Anaheim, California + 28 more

Conditions: Skin and Subcutaneous Tissue Bacterial Infections
Interventions: Delafloxacin, Vancomycin, Aztreonam, Placebo; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 17
States / cities: Montgomery, Alabama • Anaheim, California • Chula Vista, California + 14 more

Conditions: Bacterial Infections
Interventions: ceftaroline, vancomycin plus aztreonam, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 17
States / cities: Buena Park, California • Hawaiian Gardens, California • Los Angeles, California + 14 more

Conditions: Clostridium Difficile Infection Recurrence
Interventions: bezlotoxumab, Vancomycin Oral; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Staphylococcal Skin Infections
Interventions: Daptomycin, Vancomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 25
States / cities: Mobile, Alabama • Chula Vista, California • Escondido, California + 22 more

Conditions: Surgical Site Infection
Interventions: Intrasite Vancomycin, IV Vancomycin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Arthropathy of Knee Joint
Interventions: Vancomycin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Skin Infection
Interventions: Dalbavancin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Rhinosinusitis (Diagnosis)
Interventions: Mupirocin, Tobramycin, Levofloxacin, Vancomycin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea, C. Diff Colitis, C.Difficile Colitis
Interventions: Vancomycin, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Search by objective public record fields.

Next-Generation Synbiotic in Individuals With Overweight or Obesity

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections

Optimizing Vancomycin Therapy in Children

Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral

Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis

Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

IO Vancomycin Administration in TKA

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid

Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure

Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections

Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis

Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients

Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin

Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

Dose Escalation Trial of Intrasite Vancomycin Pharmacokinetics

Regional Prophylactic Vancomycin in Revision Total Knee Replacement

Hospital Avoidance Strategies for ABSSSI

Topical Antibiotics in Chronic Rhinosinusitis

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection